Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Directive Launches Expanded Communications Division, Bringing Performance Principles to B2B PR, Social and Influencer Marketing
-
Bilibili Inc. Announces Completion of US$500 Million Marketed Convertible Senior Notes Offering, Concurrent Equity Placement and Concurrent Delta Repurchase
-
U.S. Critical Minerals enters into agreements to merge with Nova Resources and acquire the historic McAllister tantalum mine and mill in Alabama
-
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
-
K2 Drills 27.43m of 4.03 g/t Au at Dragonfly, Confirms Multiple Stacked High-Grade Oxide Gold Structures
-
Koryx Copper Announces Further Drill Results at the Haib Copper Project in Southern Namibia
-
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
-
GHD selected to deliver upgrades at Skyway wastewater treatment plant in Ontario
-
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer
-
Aya Gold & Silver Announces Updated PEA for Boumadine: After-Tax NPV Doubles to $3.5B with 93% IRR
-
New Women's Health Initiative Brings Health Products, Education and Support Directly to Women Across the GTA
-
ABBYY Study Finds Business Leaders Disagree on Who Has Ultimate Responsibility When AI Goes Wrong
-
Talisker Reports Mustang Underground Face Sample Results Defining a 79-metre Strike Length High-grade Shoot Averaging 64.8 g/t on the 1030 Level
-
Honoring HR Leadership: American Express’s Monique Herena and HiBob’s Nirit Peled-Muntz Take Top Honors
-
Nobel Announces Drill Plan for the Cuprita Copper Project and Provides Update on the Janett Project
-
Lightbridge Secures Access to Idaho National Laboratory's Advanced Test Reactor Loop Facility to Irradiate Clad Lightbridge Fuel™ Rodlets Under Prototypic Commercial Reactor Conditions
-
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
-
Erdene Enters Into Automatic Securities Purchase Plan
-
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
-
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
-
Operative Launches Unified Platform to Transform Advertising & Broadcast Management
-
Aldebaran Reports 513 m of 1.06% CuEq (1.01% Cu, 0.08 g/t Au & 3.58 g/t Ag), Within 1,257.30 m of 0.66% CuEq (0.62% Cu, 0.05 g/t Au & 1.94 g/t Ag) at the Altar Copper-Gold Project in San Juan,
-
LifeStance Health Group Announces Launch of Secondary Public Offering
-
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
-
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
-
SunHydrogen CTO Details Path from Demonstrated Module Performance to Commercialization
-
INLIF LIMITED Announces Adjournment of Extraordinary General Meeting
-
GGBR Inc. Announces New Trust-Based Collateral Structure for Goldfish Tokens
-
Amplify ETFs Recognized with Two 2026 ETF Express Award Nominations
-
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
-
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
-
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+
-
ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter
-
MapLight Therapeutics to Participate in Upcoming Investor Conference
-
Destination XL Group, Inc. Reports Second Quarter Financial Results
-
NEW CHUCK E. CHEESE STATE OF THE BIRTHDAY PARTY REPORT REVEALS WHAT KIDS REALLY WANT FROM THEIR BIRTHDAY PARTIES
-
Broncos Country, This One’s for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”
-
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
-
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
-
Copper Giant Resources Corp. Begins Trading on OTCQX Best Market
-
Xanadu and ASML Announce Collaboration to Advance Lithography for Photonic Quantum Hardware
-
Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus
-
Troilus Reports Updated Technical Report Following Completion of Basic Engineering, Delivering After-Tax US$3.2 Billion NPV5%, 22% IRR, and Cashflow of US$6.9 Billion at Base Case Gold Price of US $3,
-
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
-
Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
-
Fractyl Health to Participate in Upcoming September Investor Conferences
-
Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)
-
SailPoint Announces Fiscal Second Quarter 2027 Results
-
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
-
Accumulus Technologies Announces Acquisition by Eir Partners to Accelerate Next Phase of Growth
